Imzokitug

N/A

Report date: 2026/02/20 20:02:00

Base Information

Drug NameImzokitug
Drug Alias NameBMS-986340ONO-7427
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes inhibitorsC-C chemokine receptor type 8 inhibitors
TargetsC-C chemokine receptor type 8
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell Lung +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesItaly +[9] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesEeig Bristol-Myers Squibb Manufacturing Company Bristol-Myers Squibb Srl
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyBristol-Myers Squibb (China) Investment Co LtdBristol-Myers Squibb Company
Inactive CompaniesThe University Of Texas MD Anderson Cancer CenterEeig Bristol-Myers Squibb Manufacturing Company Bristol-Myers Squibb Srl
Active IndicationsSolid tumoursUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell Lung +[12] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A